User:Mr. Ibrahem/Palbociclib

Mr. Ibrahem/Palbociclib
Clinical data
Trade names	Ibrance, others
Other names	PD-0332991
AHFS/Drugs.com	Monograph
MedlinePlus	a615013
License data	EU EMA: by INN; US DailyMed: Palbociclib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth (capsules)
Drug class	CDK4 and CDK6 inhibitor
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	46%
Protein binding	85%
Metabolism	Liver (CYP3A, SULT2A1, glucuronidation)
Elimination half-life	29 (±5) hours
Excretion	74% feces, 18% urine
Identifiers
	IUPAC name 6-Acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one;
Chemical and physical data
Formula	C24H29N7O2
Molar mass	447.543 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(c1nc(ncc1/C(=C2/C(=O)C)C)Nc3ncc(cc3)N4CCNCC4)C5CCCC5;
	InChI InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29); Key:AHJRHEGDXFFMBM-UHFFFAOYSA-N;

Palbociclib, sold under the brand name Ibrance among others, is a medication used to treat breast cancer.^[2] Specifically it is used for hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2 (HER2) negative advanced disease.^[2] It is taken by mouth.^[2]

Common side effects include hair loss, low red blood cells, diarrhea, nose bleedings, infection, rash, and vomiting.^[1] Other side effects may include liver problems, pneumonitis, and infertility.^[2]^[3] Use during pregnancy may harm the baby.^[1] It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.^[1]

Palbociclib was approved for medical use in the United States in 2015 and Europe in 2016.^[2]^[3] In the United Kingdom 4 weeks of medication costs the NHS about £3,000 as of 2021.^[1] This amount in the United States costs about 13,700 USD.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1050. ISBN 978-0-85711-369-6.
^ ^a ^b ^c ^d ^e ^f "Palbociclib Monograph for Professionals". Drugs.com. Archived from the original on 11 August 2020. Retrieved 20 October 2021.
^ ^a ^b "Ibrance". Archived from the original on 9 August 2021. Retrieved 22 October 2021.
^ "Ibrance Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 22 October 2021.

[BNF80-1] ^ ^a ^b ^c ^d ^e ^f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1050. ISBN 978-0-85711-369-6.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f "Palbociclib Monograph for Professionals". Drugs.com. Archived from the original on 11 August 2020. Retrieved 20 October 2021.

[EPAR2021-3] "Ibrance". Archived from the original on 9 August 2021. Retrieved 22 October 2021.

[4] "Ibrance Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 22 October 2021.

[1]

[2]

[3]

[4]